A shutdown of manufacturing facilities in Shanghai that has since been resolved led to a shortage of iohexol injection, an iodinated contrast medium (ICM) essential to many interventional pain procedures. The supply of other ICMs—used to confirm accurate needle placement, injectate delivery and exclude flow of off-target tissue—is now compromised, and the shortages will most likely continue while production of iohexol injection continues to ramp up.
As such, the American Society of